Press Releases

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.

Date	Title and Summary	Additional Formats
Toggle SummaryMay282014	Fate Therapeutics to Present at Jefferies 2014 Global Healthcare Conference SAN DIEGO, May 28, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer, Read All »	View HTML Fate Therapeutics to Present at Jefferies 2014 Global Healthcare Conference 10.1 KB
Toggle SummaryJun052014	Fate Therapeutics to Highlight Potential Clinical Applications of Ex Vivo Hematopoietic Cell Modulation at 12th International Cord Blood Symposium SAN DIEGO, June 5, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today announced that potential clinical applications of its ex vivo approach to Read All »	View HTML Fate Therapeutics to Highlight Potential Clinical Applications of Ex Vivo Hematopoietic Cell Modulation at 12th International Cord Blood Symposium 16.7 KB
Toggle SummaryJun302014	Fate Therapeutics Submits IND Application for the Clinical Development of PROHEMA(R) in Inherited Metabolic Disorders SAN DIEGO , June 30, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that it has submitted an investigational new drug (IND) application to Read All »	View HTML Fate Therapeutics Submits IND Application for the Clinical Development of PROHEMA(R) in Inherited Metabolic Disorders 21.5 KB
Toggle SummaryJul292014	Fate Therapeutics Announces FDA Clearance of IND for Clinical Development of PROHEMA in Inherited Metabolic Disorders Phase 1b PROVIDE Study in Pediatric Patients with Inherited Metabolic Disorders Expected to Begin in 4Q14 Read All »	View HTML Fate Therapeutics Announces FDA Clearance of IND for Clinical Development of PROHEMA in Inherited Metabolic Disorders 16.8 KB
Toggle SummaryJul312014	Fate Therapeutics Secures Up to $20 Million in Debt Financing Strengthened Cash Position Expected to Fund Company Through 2015 Read All »	View HTML Fate Therapeutics Secures Up to $20 Million in Debt Financing 15.3 KB
Toggle SummaryAug052014	Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2014 Financial Results on August 12, 2014 SAN DIEGO, Aug. 5, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today announced that the Company will host a conference call and live audio webcast on Read All »	View HTML Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2014 Financial Results on August 12, 2014 10.4 KB
Toggle SummaryAug122014	Fate Therapeutics Reports Second Quarter 2014 Financial Results First Data Review in Phase 2 PUMA Study of PROHEMA Supports Continuation of Enrollment PROMPT and PROVIDE Studies of PROHEMA in Pediatric Patients to Initiate in 2H14 SAN DIEGO, Aug. 12, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the Read All »	View HTML Fate Therapeutics Reports Second Quarter 2014 Financial Results 29.6 KB
Toggle SummarySep032014	Fate Therapeutics to Present at Rodman & Renshaw 16th Annual Global Investment Conference SAN DIEGO, Sept. 3, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer Read All »	View HTML Fate Therapeutics to Present at Rodman & Renshaw 16th Annual Global Investment Conference 10.1 KB
Toggle SummaryOct302014	Fate Therapeutics to Present at Nomura Biotechnology Conference SAN DIEGO, Oct. 30, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer Read All »	View HTML Fate Therapeutics to Present at Nomura Biotechnology Conference 10.2 KB
Toggle SummaryNov042014	Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2014 Financial Results on November 11, 2014 SAN DIEGO, Nov. 4, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today announced that the Company will host a conference call and live audio webcast on Read All »	View HTML Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2014 Financial Results on November 11, 2014 11 KB
Toggle SummaryNov112014	Fate Therapeutics Reports Third Quarter 2014 Financial Results Phase 1b PROMPT Study in Pediatric Hematologic Malignancies Open for Enrollment Second Data Review in Phase 2 PUMA Study Expected in 4Q14 Presenting Effects of Ex Vivo Programming on Mobilized Peripheral Blood at ASH SAN DIEGO, Nov. 11, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. Read All »	View HTML Fate Therapeutics Reports Third Quarter 2014 Financial Results 30.1 KB
Toggle SummaryNov252014	Fate Therapeutics to Present at Piper Jaffray 26th Annual Healthcare Conference SAN DIEGO, Nov. 25, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer, Read All »	View HTML Fate Therapeutics to Present at Piper Jaffray 26th Annual Healthcare Conference 10.8 KB
Toggle SummaryDec062014	Fate Therapeutics Unveils Preclinical Findings of Newly-Identified Small Molecule Modulator Combination for Ex Vivo Programming of Mobilized Peripheral Blood Expression of Genes Involved in T-cell Function and Hematopoietic Stem Cell Engraftment Significantly Increased Read All »	View HTML Fate Therapeutics Unveils Preclinical Findings of Newly-Identified Small Molecule Modulator Combination for Ex Vivo Programming of Mobilized Peripheral Blood 22.9 KB
Toggle SummaryDec082014	Fate Therapeutics Highlights Effects of Nutrient-Rich Media on Ex Vivo Programmed CD34+ Cells Sourced From Umbilical Cord Blood SAN DIEGO , Dec. 8, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, will present today an overview of the effects of using its nutrient-rich media (NRM) Read All »	View HTML Fate Therapeutics Highlights Effects of Nutrient-Rich Media on Ex Vivo Programmed CD34+ Cells Sourced From Umbilical Cord Blood 22.4 KB
Toggle SummaryDec182014	Fate Therapeutics Announces Interim Data From Ongoing Phase 2 PUMA Study Key Metrics of Neutrophil Engraftment Improved in PROHEMA Arm Independent Data Monitoring Committee Supports Continuation of Study Enrollment Full Results on Primary Efficacy Endpoint Expected in mid-2015 SAN DIEGO, Dec. 18, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. Read All »	View HTML Fate Therapeutics Announces Interim Data From Ongoing Phase 2 PUMA Study 24.4 KB